Retour
Également cotée sous
HLBBF
OTC
Fourchette du Jour
4,82 €
5,37 €
Fourchette 52 Semaines
3,67 €
6,41 €
Volume
1
Moyenne 50J / 200J
5,61 €
/
5,13 €
Clôture Précédente
4,82 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 1,5 | 0,4 |
| P/B | 0,2 | 2,9 |
| ROE % | 12,8 | 3,9 |
| Net Margin % | 13,1 | 3,8 |
| Rev Growth 5Y % | 10,5 | 10,0 |
| D/E | 0,5 | 0,2 |
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
0,00 €
0,00 € – 0,00 €
|
26 B | 0 |
| FY2026 |
0,00 €
0,00 € – 0,00 €
|
25 B | 0 |
Points Clés
Revenue grew 10,50% annually over 5 years — strong growth
ROE of 12,78% — decent returns on equity
Debt/Equity of 0,48 — conservative balance sheet
Generating 4,33B in free cash flow
P/E of 1,50 — trading at a low valuation
Cash machine — converts 136,09% of earnings into free cash flow
Croissance
Revenue Growth (5Y)
10,50%
Revenue (1Y)10,42%
Earnings (1Y)1,33%
FCF Growth (3Y)10,05%
Qualité
Return on Equity
12,78%
ROIC12,87%
Net Margin13,11%
Op. Margin26,05%
Sécurité
Debt / Equity
0,48
Current Ratio1,44
Interest Coverage11,72
Valorisation
P/E Ratio
1,50
P/B Ratio0,19
EV/EBITDA2,11
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10,42% | Revenue Growth (3Y) | 10,46% |
| Earnings Growth (1Y) | 1,33% | Earnings Growth (3Y) | 17,93% |
| Revenue Growth (5Y) | 10,50% | Earnings Growth (5Y) | 24,68% |
| Profitability | |||
| Revenue (TTM) | 24,30B | Net Income (TTM) | 3,18B |
| ROE | 12,78% | ROA | 5,91% |
| Gross Margin | 79,58% | Operating Margin | 26,05% |
| Net Margin | 13,11% | Free Cash Flow (TTM) | 4,33B |
| ROIC | 12,87% | FCF Growth (3Y) | 10,05% |
| Safety | |||
| Debt / Equity | 0,48 | Current Ratio | 1,44 |
| Interest Coverage | 11,72 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 1,50 | P/B Ratio | 0,19 |
| P/S Ratio | 0,20 | PEG Ratio | 8,40 |
| EV/EBITDA | 2,11 | Dividend Yield | 0,03% |
| Market Cap | 4,78B | Enterprise Value | 13,37B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 24,30B | 22,00B | 19,91B | 18,25B | 16,30B |
| Net Income | 3,18B | 3,14B | 2,29B | 1,92B | 1,32B |
| EPS (Diluted) | 3,21 | 3,17 | 2,31 | 1,93 | 1,33 |
| Gross Profit | 19,33B | 17,77B | 15,43B | 14,30B | 12,65B |
| Operating Income | 6,33B | 3,27B | 3,20B | 2,85B | 2,01B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 53,89B | 56,98B | 37,41B | 37,45B | 34,65B |
| Total Liabilities | 29,04B | 31,97B | 15,36B | 16,67B | 16,37B |
| Shareholders' Equity | 24,85B | 25,01B | 22,05B | 20,78B | 18,28B |
| Total Debt | 12,02B | 16,69B | 4,15B | 5,58B | 5,32B |
| Cash & Equivalents | 3,43B | 4,66B | 5,01B | 3,42B | 2,28B |
| Current Assets | 12,75B | 13,01B | 13,29B | 11,41B | 8,61B |
| Current Liabilities | 8,83B | 8,58B | 7,99B | 8,20B | 8,82B |
Scores de Stratégies
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Activité Récente
Entré
Cash Flow Compounder
Mar 24, 2026
Entré
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entré
Defensive Investing (Benjamin Graham)
Mar 24, 2026